TECH
NasdaqGSBio-Techne Corporation
Price
Key statistics
Insider activity
SEC EDGAR ↗Showing 30 recent filings. 29 other (grants, option exercises, gifts, tax withholding) are listed below but excluded from buy/sell flow.
| Insider | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|
Crouse Steven C. President - Diag & Spatial Bi | Option exercise | 600 | — | — | 2026-06-02 |
Crouse Steven C. President - Diag & Spatial Bi | Tax withholding | 216 | $49.77 | $10,750.32 | 2026-06-02 |
Crouse Steven C. President - Diag & Spatial Bi | Option exercise | 600 | $0.00 | — | 2026-06-02 |
Herr Amy E. Director | Option exercise | 6.64K | $47.60 | $315,873.60 | 2026-05-08 |
Herr Amy E. Director | Sell (open market) | 6.64K | $48.28 | $320,386.08 | 2026-05-08 |
Herr Amy E. Director | Option exercise | 6.64K | $0.00 | — | 2026-05-08 |
Hippel James CFO | Option exercise | 62K | $47.60 | $2,951,200.00 | 2026-05-05 |
Hippel James CFO | Tax withholding | 56.96K | $56.68 | $3,228,209.40 | 2026-05-05 |
Hippel James CFO | Option exercise | 62K | $0.00 | — | 2026-05-05 |
Bohnen Shane SVP - General Counsel | Option exercise | 8.4K | $47.60 | $399,840.00 | 2026-05-05 |
Bohnen Shane SVP - General Counsel | Tax withholding | 7.06K | $56.68 | $399,877.40 | 2026-05-05 |
Bohnen Shane SVP - General Counsel | Option exercise | 8.4K | $0.00 | — | 2026-05-05 |
Kelderman Kim Director, Chief Executive Officer | Option exercise | 26.69K | $47.60 | $1,270,539.20 | 2026-05-05 |
Kelderman Kim Director, Chief Executive Officer | Tax withholding | 23.95K | $56.68 | $1,357,542.68 | 2026-05-05 |
Kelderman Kim Director, Chief Executive Officer | Option exercise | 26.69K | $0.00 | — | 2026-05-05 |
Crouse Steven C. President - Diag & Spatial Bi | Option exercise | 794 | — | — | 2026-05-01 |
Crouse Steven C. President - Diag & Spatial Bi | Tax withholding | 311 | $55.02 | $17,111.22 | 2026-05-01 |
Crouse Steven C. President - Diag & Spatial Bi | Option exercise | 794 | $0.00 | — | 2026-05-01 |
Kelderman Kim Director, Chief Executive Officer | Option exercise | 11.34K | $0.00 | — | 2026-04-22 |
Kelderman Kim Director, Chief Executive Officer | Tax withholding | 1.36K | $58.58 | $79,844.54 | 2026-04-22 |
Kelderman Kim Director, Chief Executive Officer | Option exercise | 11.34K | $0.00 | — | 2026-04-22 |
Hippel James CFO | Option exercise | 62K | $0.00 | — | 2026-04-22 |
Hippel James CFO | Tax withholding | 56.1K | $58.58 | $3,286,162.26 | 2026-04-22 |
Hippel James CFO | Option exercise | 62K | $0.00 | — | 2026-04-22 |
Kelderman Kim Director, Chief Executive Officer | Option exercise | 36.5K | $0.00 | — | 2026-04-14 |
Kelderman Kim Director, Chief Executive Officer | Tax withholding | 32.09K | $58.66 | $1,882,282.08 | 2026-04-14 |
Kelderman Kim Director, Chief Executive Officer | Option exercise | 36.5K | $0.00 | — | 2026-04-14 |
Bohnen Shane SVP - General Counsel | Option exercise | 2.26K | $0.00 | — | 2026-04-03 |
Bohnen Shane SVP - General Counsel | Tax withholding | 740 | $53.13 | $39,316.20 | 2026-04-03 |
Bohnen Shane SVP - General Counsel | Option exercise | 2.26K | $0.00 | — | 2026-04-03 |
Source: SEC EDGAR Forms 4/4A (CIK 842023). Click an insider to open the original filing.
Social sentiment
Volume-weighted across live social sources
$ALT Regarding the question about growing short interest: I’ve noticed several times that short interest increased significantly and kept rising right up until the buyout of certain biotech companies. I asked ChatGPT to list the major biotech buyouts in 2026. The results are $TECH, $APGE, and $FOLD. Interestingly, all of them showed elevated or growing short interest leading up to the acquisition announcement. 👇
$TECH TECH Price Target Alert: $73.00. Issued by Deutsche Bank https://marketwirenews.com/stock/tech/news/tech-price-target-alert-73-00-issued-by-deutsche-ban-5447941763202062.html?utm_source=stocktwits
$TECH Hold Recommendation Issued On TECH By Deutsche Bank https://marketwirenews.com/stock/tech/news/hold-recommendation-issued-on-tech-by-deutsche-bank-5939493996299149.html?utm_source=stocktwits
$AYI +21.5% $TECH +20.09% $MU +15.78% $SNDK +17.4% $QCOM +9% to +10% https://truthsandnews.com/markets/top-stock-gainers-today-june-25-2026
$TECH Stock Market Today, June 25: Bio-Techne Surges After Merck KGaA Announces $73-PER-SHARE Cash Acquisition Offer https://marketwirenews.com/stock/tech/news/stock-market-today-june-25-bio-techne-surges-after-m-7238764970778849.html?utm_source=stocktwits
$TECH TECH Price Target Alert: $73.00. Issued by Leerink Partners https://marketwirenews.com/stock/tech/news/tech-price-target-alert-73-00-issued-by-leerink-part-7973092496092934.html?utm_source=stocktwits
$TECH gapping to 70.50, up almost 20% on the session, Merck buying them out for $11.3B. M&A names like this usually pin near the deal price and go dead. anyone playing the arb spread here or just letting it sit? this is what my scanner flagged: https://tapeboard.com/scanner?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=tech-bk-up-scanner&utm_term=scanner&s=TECH
$MU $SNDK $TECH $BB $KYMR 👏🏼👏🏼👏🏼👊🏻👊🏻👊🏻
$TECH had a small position that I was building in my multi bagger account. Sold this morning. Getting bought out is definitely a risk when researching companies of this nature. On to finding a replacement or just adding to existing names.
$TECH Good call dude
$TECH popping 19% to 70 on the Merck KGaA buyout, 11.3B all cash. these deal pops usually pin near the offer and grind sideways from here, no real trade left unless arb is your thing. anyone playing the spread or just moving on? this is what my scanner flagged: https://tapeboard.com/scanner?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=tech-bk-up-scanner&utm_term=scanner&s=TECH
$TECH I guess exactly there. I sold most of my shares for 58 assuming it would eventually sell off again. Oh well gains a gain. I would be more disappointed after holding this into S&P inclusion to get a 80 point haircut to then only get offered half of the orginal inclusion market cap.
Latest news
Q1 Earnings Outperformers: Bio-Techne (NASDAQ:TECH) And The Rest Of The Research Tools & Consumables Stocks
RBC Capital Downgrades Bio-Techne to Sector Perform From Outperform, Adjusts Price Target to $73 From $62
Bio-Techne Expands AI-Engineered Designer Protein Portfolio
Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio
Evercore ISI Downgrades Bio-Techne to In Line From Outperform, Maintains $73 Price Target
SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation
Piper Sandler Adjusts Bio-Techne Price Target to $73 From $60, Maintains Neutral Rating
Benchmark Downgrades Bio-Techne to Hold From Buy
TD Cowen Downgrades Bio-Techne to Hold From Buy, Adjusts Price Target to $73 From $65
1 Momentum Stock with Impressive Fundamentals and 2 We Find Risky
Get insider-buy alerts
Free weekly digest of the most notable SEC insider purchases — plus early access to real-time alerts on your watchlist.